The PEAK25-cohort, women 25 yrs at inclusion, addresses factors contributing to peak bone mass. In 2014 the PEAK25 cohort is still unique since there are no cohorts nationally or internationally which have been specifically designed to identify genetic and other risk factors for bone strength at this critical age or which has been followed longitudinally. By investigating 10yr change in BMD we have the potential to identify genes important for bone homeostasis, without confounding from perimenopausal hormonal changes. Parents and grand-parents have also been collected. This cohort is an important resource in terms of providing normative data for young Swedish women, providing reference data for future studies in women and investigating long-term changes in risk factors in pre-menopausal women. In PEAK-25, a total of 1,061 (response rate 49 %) underwent baseline investigation (1999-2004). Enrollment was continuous throughout the year to avoid seasonal bias. All women were 25 years old at inclusion. Exclusion criteria was pregnancy at the time of the baseline investigation or during the 12 months prior to inclusion. The cohort was followed up at 10-years. The investigations included bone mineral density (BMD) and body composition measurements, anthropometrics and BioDex isokinetic muscle force. Questionnaires provide information on lifestyle, recreational physical activity, health, food/nutrition, birthweight and hormonal function. Validated instruments for outcome (SF-36, EQ5D and Qualeffo-radius), ADL-function are also available. Information on fractures sustained prior to baseline and during followup were collected. Blood and urine samples were collected. Extensive phenotyping includes: bone turnover markers and a number of serum markers GWAS genotyping will be available in Spring 2017 (Illumina GSA Arrays “Infinium iSelect 24x1 HTS Custom Beadchip Kit”). Purpose: This cohort was designed to include women at an age closely representing ‘pure’ peak bone mass, prior to any major perturbations from external or internal factors causing loss of bone. Essentially it is a period of intact coupling between bone formation and resorption. The aim of the study was identification of gene variants and other associated risk factors for osteoporosis on the attainment of peak bone mass.
The performance of the basic activities of self care, such as dressing, ambulation, or eating.
The taking of a blood sample to determine its character as a whole, to identify levels of its component cells, chemicals, gases, or other constituents, to perform pathological examination, etc.
The relative amounts of various components in the body, such as percentage of body fat.
Studies in which variables relating to an individual or group of individuals are assessed over a period of time.
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
Methods or procedures used to obtain samples of URINE.
Human females as cultural, psychological, sociological, political, and economic entities.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS.
The science devoted to the comparative study of man.
The period before MENOPAUSE. In premenopausal women, the climacteric transition from full sexual maturity to cessation of ovarian cycle takes place between the age of late thirty and early fifty.
documentation/List of publicationsPEAK25.pdf